Emergent BioSolutions Inc (EBS)
9.27
-0.70
(-7.02%)
USD |
NYSE |
Nov 14, 16:00
9.17
-0.10
(-1.08%)
Pre-Market: 20:00
Emergent BioSolutions Free Cash Flow (Quarterly): 147.90M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 147.90M |
| June 30, 2024 | 42.90M |
| March 31, 2024 | -73.40M |
| December 31, 2023 | 20.70M |
| September 30, 2023 | 47.40M |
| June 30, 2023 | -126.90M |
| March 31, 2023 | -199.10M |
| December 31, 2022 | 69.20M |
| September 30, 2022 | -101.90M |
| June 30, 2022 | -47.70M |
| March 31, 2022 | -69.50M |
| December 31, 2021 | 282.30M |
| September 30, 2021 | -38.50M |
| June 30, 2021 | -96.70M |
| March 31, 2021 | -51.00M |
| December 31, 2020 | 209.10M |
| September 30, 2020 | 59.50M |
| June 30, 2020 | 92.80M |
| March 31, 2020 | 33.60M |
| December 31, 2019 | 86.00M |
| September 30, 2019 | -18.40M |
| June 30, 2019 | -49.90M |
| March 31, 2019 | 83.40M |
| December 31, 2018 | -186.60M |
| September 30, 2018 | 147.90M |
| Date | Value |
|---|---|
| June 30, 2018 | 21.00M |
| March 31, 2018 | -12.60M |
| December 31, 2017 | 65.07M |
| September 30, 2017 | 22.16M |
| June 30, 2017 | 44.70M |
| March 31, 2017 | 21.37M |
| December 31, 2016 | -32.61M |
| September 30, 2016 | 10.08M |
| June 30, 2016 | -23.03M |
| March 31, 2016 | 23.96M |
| December 31, 2015 | -10.05M |
| September 30, 2015 | 90.81M |
| June 30, 2015 | -8.096M |
| March 31, 2015 | -74.96M |
| December 31, 2014 | 35.77M |
| September 30, 2014 | 73.70M |
| June 30, 2014 | 6.009M |
| March 31, 2014 | -33.84M |
| December 31, 2013 | 1.04M |
| September 30, 2013 | 39.83M |
| June 30, 2013 | 26.38M |
| March 31, 2013 | -12.30M |
| December 31, 2012 | -51.92M |
| September 30, 2012 | 36.46M |
| June 30, 2012 | 9.746M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-199.10M
Minimum
Mar 2023
282.30M
Maximum
Dec 2021
14.34M
Average
27.15M
Median
Free Cash Flow (Quarterly) Benchmarks
| Geovax Labs Inc | -1.941M |
| Tonix Pharmaceuticals Holding Corp | -9.919M |
| Abbott Laboratories | 2.149B |
| SIGA Technologies Inc | -7.406M |
| Chimerix Inc | -20.53M |